Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ALIVUS

ALIVUS

HealthcarePharmaceuticals & Biotechnology₹17740 cr market cap
₹1449.90 ▲ +0.36% today As of 19 Nov 2026
52-week low ₹860.0552-week high ₹1520.70

-5.0% from the 52-week high · +68.0% above the low

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra and currently employs 1,824 full-time employees. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

The short version. Promoter holding was 74.85% in Sep 2026, down 0.15 points over 8 quarters.

1 · The price

How has the stock traded?

ALIVUS trades 5.0% below its 52-week high and 68.0% above its 52-week low.

Change over period: —

1M+13.9%
3M+5.5%
6M+36.2%
1Y+56.4%

4 · The owners

Who holds it, and are they adding?

Promoter holding74.85%

Down 0.15 pts over 8 quarters.

Foreign institutions5.93%

Down 0.81 pts over 8 quarters.

Domestic institutions7.03%

Up 2.17 pts over 8 quarters.

Mutual fund schemes15

+2 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter75.074.9974.9474.9174.9174.8774.8774.85-0.15
FII6.746.576.426.845.095.295.545.93-0.81
DII4.865.195.615.477.127.287.187.03+2.17
Public13.413.2513.0312.7812.8812.5612.4112.19-1.21

Mutual fund holdings · Oct 2026

15 schemes hold this stock

13 the month before.

  • Old Bridge Focused Fund4.13% of NAV
  • the Quantum Small Cap Fund2.84% of NAV
  • quant Healthcare Fund2.34% of NAV
  • quant Flexi Cap Fund2.15% of NAV
  • Unifi Flexi Cap Fund1.12% of NAV
  • Bandhan Contra Fund1.0% of NAV
  • Helios Small Cap Fund0.94% of NAV
  • quant Small Cap Fund0.93% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ALIVUS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ALIVUS

What is the ALIVUS share price?

ALIVUS (ALIVUS) last closed at ₹1,449.90, up 0.36% on the day. Its 52-week range is ₹860.05 to ₹1,520.70.

What is the market cap of ALIVUS?

ALIVUS has a market capitalisation of about ₹17,740 crore. Its price-to-earnings ratio is 26.6.

How are ALIVUS's latest results?

Promoter holding was 74.85% in Sep 2026, down 0.15 points over 8 quarters.

Who owns ALIVUS?

As of Sep 2026, shareholding was: Promoter 74.85%, FII 5.93%, DII 7.03%, Public 12.19%.

How many mutual funds hold ALIVUS?

15 mutual fund schemes held ALIVUS in October 2026. That compares with 13 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 01 Sep 2025 · Final Dividend - Rs. 5
  • 17 Oct 2023 · Interim Dividend - Rs. 22.5
  • 24 Mar 2023 · Interim Dividend - Rs. 21
  • 15 Sep 2022 · Final Dividend - Rs. 10.5
  • 22 Nov 2021 · Interim Dividend - Rs. 10.5

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.